1361563-03-2

1361563-03-2 structure

Name: Aldoxorubicin•HCl
Chemical Name: Aldoxorubicin hydrochloride
CAS Number: 1361563-03-2
Molecular Formula: C₃₇H₄₃ClN₄O₁₃
Molecular Weight: 787.21
Catalog: Signaling Pathways Antibody-drug Conjugate ADC Cytotoxin
Create Date: 2019-06-16 15:21:31
Modify Date: 2024-01-02 19:13:21
Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.

Name	Aldoxorubicin hydrochloride
Synonyms	S098K6HGD9 Aldoxorubicin hydrochloride N'-[(1E)-1-{(2S,4S)-4-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro -1H-pyrrol-1-yl)hexanehydrazide hydrochloride (1:1) 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[(1E)-1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphth acenyl]-2-hydroxyethylidene]hydrazide, hydrochloride (1:1) MFCD25371995

Description	Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Signaling Pathways >> Antibody-drug Conjugate >> ADC Cytotoxin
Target	Topoisomerase II[4]
In Vitro	Aldoxorubicin hydrochloride (INNO-206)? (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion[1].
In Vivo	Aldoxorubicin hydrochloride (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor[1]. Aldoxorubicin hydrochloride (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study[2]. Aldoxorubicin hydrochloride (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models[3].
References	[1]. Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32. [2]. Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F [3]. Eric Sanchez, et al. Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. Clin Cancer Res.2012 18; 3856. [4]. Kratz, F. INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies. Current Bioactive Compounds, 2011, 7(1): 33-38(6)

Molecular Formula	C₃₇H₄₃ClN₄O₁₃
Molecular Weight	787.21
Exact Mass	786.251526
Appearance	Powder
Storage condition	store at -20℃ for one year（Powder）

1361563-03-2	1782228-59-4
1807453-83-3	1246820-88-1
1078162-99-8	1181457-78-2
1193387-39-1	1193390-03-2
1181458-44-5	1049778-21-3
1158522-08-7	940364-43-2
1774895-94-1	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1375289-11-4	849349-65-1